Opendata, web and dolomites

IRL790

NOVEL THERAPEUTIC FOR THE TREATMENT OF PARKINSONS DISEASE

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IRL790 project word cloud

Explore the words cloud of the IRL790 project. It provides you a very rough idea of what is the project "IRL790" about.

discovery    psychosis    severe    symptomatic    cns    patients    screening    healthcare    diseases    market    investors    innovation    treatment    dalys    clinical    contact    grant    trials    therapeutic    rates    combats    gt    safety    outcomes    besides    worldwide    medical    sme    prevalence    developmental    candidates    providers    disease    bodies    national    trust    compound    disability    drug    million    proprietary    levodopa    burden    motor    validated    benefits    irl790    isp    network    tolerability    prescribed    intervention    data    reducing    indications    sooner    superior    complexities    clinic    savings    license    irlab    2018    yields    symptoms    platform    debilitating    highest    neurodegenerative    gained    people    lids    successful    business    life    psychotic    pd    ago    captures    chance    ongoing    clinically    efficacy    complications    international    dyskinesia    parkinson    accelerate    licensing    plan    disorder    neurological    generation    adjusted    death    relief    validating    leads    integrative    quality    simultaneously   

Project "IRL790" data sheet

The following table provides information about the project.

Coordinator
INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB 

Organization address
address: ARVID WALLGRENS BACKE 20
city: GOTEBORG
postcode: 413 46
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.irlab.se/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB SE (GOTEBORG) coordinator 50˙000.00

Map

 Project objective

This project’s goal is to develop a successful treatment that combats severe motor and psychotic symptoms in Parkinson’s disease (PD). PD is a debilitating neurodegenerative disorder affecting > 6 million people worldwide. It’s the neurological disorder with the highest increase in death rates, prevalence, and disability-adjusted life-years (DALYs). Levodopa, introduced more than 50 years ago, remains the most prescribed treatment for the symptomatic relief of PD, although its long-term use leads to the development of motor complications, i.e. levodopa-induced dyskinesia (PD-LIDs). IRLAB aims to address the challenge in PD treatment by clinically validating its novel compound, IRL790, aimed at reducing symptoms of PD-LIDs and Parkinson’s disease psychosis. IRLAB’s programme is based on its proprietary drug discovery platform, Integrative Screening Process (ISP), which captures a better understanding of complexities of CNS-related diseases, such as PD, and yields drug candidates with superior chance of success in the clinic. IRLAB’s therapeutic will improve intervention outcomes for PD patients in two indications. Its safety and tolerability have been validated in Phase I clinical trials and its therapeutic efficacy in PD-LIDs is being evaluated in an ongoing Phase II study. Results are expected 2018. Besides medical benefits to patients, IRL790 has also the potential to bring cost-savings to healthcare providers by effectively reducing the Parkinson’s disease burden. Generation of high quality clinical data will improve IRLAB’s opportunities for out-licensing. We plan to apply for SME grant to accelerate clinical developmental and take IRL790 through a Phase II study in PD psychosis. This way, we will out-license and market the drug sooner and for two indications (PD-LIDs and PD psychosis) simultaneously. IRLAB has an established business development contact network and have gained trust of international healthcare investors and national innovation funding bodies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IRL790" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IRL790" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

HAC (2019)

ADVANCED TREATMENT OF CONTAMINATED SOIL

Read More  

Yodiwo FEMP (2019)

An eco-friendly, Integrated Facility and Energy Management Platform for continuous reduction of infrastructure operating cost, driven by AI.

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More